Workflow
AptarGroup(ATR)
icon
Search documents
Here's Why You Should Add AptarGroup Stock to Your Portfolio Now
ZACKS· 2025-05-21 17:11
Core Viewpoint - AptarGroup, Inc. (ATR) is positioned for growth through its business transformation plan, innovative product launches, and strategic acquisitions [1] Group 1: Business Transformation - The company is focused on business transformation to drive top-line growth, enhance operational excellence, and improve organizational effectiveness [2] - The Beauty segment is undergoing transformation with new capabilities in Asia, cost reduction, and strategies to capitalize on fast-growing application fields [3] Group 2: Segmental Demand - The Pharma segment is experiencing strong demand for proprietary dispensing devices used in various medical applications, with a long-term sales growth target of 7-11% [4] - The Beauty segment is seeing increased sales in prestige and mass fragrances, as well as skin care and color cosmetic solutions, supported by a positive mix of pricing and volume growth [5] Group 3: Strategic Acquisitions - AptarGroup is committed to expanding through acquisitions to enhance technology, geographic presence, and product offerings [5] - In February 2024, Aptar Digital Health acquired Healint to strengthen its digital health portfolio in neurology and signed an agreement with Biogen for digital health solutions [6] - In October 2024, AptarGroup acquired SipNose Nasal Delivery Systems' device technology assets to enhance its intranasal delivery product development [7] Group 4: Innovative Product Launches - The Pharma segment had the highest number of product launches since 2018, with continued momentum expected in 2024 and 2025 [7] - Notable product applications include a nasal delivery system for saline rinse in Germany and an ophthalmic squeeze dispenser in China [8] - In the Beauty segment, various custom dispensing solutions are being utilized by major brands such as L'Oreal and P&G [9] Group 5: Market Performance - ATR shares have increased by 7.8% over the past year, contrasting with a 6.3% decline in the industry [12]
Surging Earnings Estimates Signal Upside for AptarGroup (ATR) Stock
ZACKS· 2025-05-19 17:21
AptarGroup (ATR) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.Analysts' growing optimism on the earnings prospects of this maker of consumer-product dispensing systems is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate re ...
AptarGroup (ATR) Upgraded to Strong Buy: Here's What You Should Know
ZACKS· 2025-05-19 17:01
AptarGroup (ATR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...
AptarGroup Earnings Surpass Estimates in Q1, Shares Rise 1%
ZACKS· 2025-05-08 17:40
Core Insights - AptarGroup, Inc. reported improved margins in Q1 2025, with adjusted earnings per share of $1.20, surpassing the Zacks Consensus Estimate of $1.16, although it represented a 1.6% decrease from $1.22 in the same quarter last year [1][2] Financial Performance - Total revenues for Q1 2025 decreased by 3.1% year over year to $887 million, missing the Zacks Consensus Estimate of $900 million, with core sales remaining flat [3] - Cost of sales fell by 5.5% year over year to $551 million, while gross profit increased by 1.1% to $336 million, resulting in a gross margin of 37.9%, up from 36.3% in the prior year [3] - Selling, research, development, and administrative expenses rose by 1.6% year over year to $155 million, with adjusted operating income increasing by 2.8% to $118 million, leading to an adjusted operating margin of 13.3%, up from 12.5% [4] Segment Performance - The Pharma segment saw a revenue increase of 0.5% year over year to $409.5 million, exceeding the estimate of $403 million, with adjusted operating income rising by 7.7% to $111 million [5] - The Beauty segment experienced a revenue decline of 6.6% year over year to $306 million, falling short of the estimated $313 million, while operating income decreased by 14.2% to $17 million [6] - The Closures segment's revenues decreased by 4.8% year over year to $172 million, also missing the estimate of $179 million, but operating income slightly increased to $13.7 million [7] Cash Position - As of March 31, 2025, AptarGroup reported cash and cash equivalents of $126 million, down from $224 million at the end of 2024, with cash flow from operations at $83 million compared to $92 million in the previous year [8] Future Outlook - The company estimates adjusted earnings per share for Q2 2024 to be between $1.56 and $1.64 [9] Stock Performance - ATR shares have increased by 2.7% over the past year, contrasting with a 12% decline in the industry [10]
3 Reasons Growth Investors Will Love AptarGroup (ATR)
ZACKS· 2025-05-07 17:45
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Gr ...
AptarGroup(ATR) - 2025 Q1 - Quarterly Report
2025-05-02 14:29
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 1-11846 AptarGroup, Inc. Delaware 36-3853103 (State of Incorporation) (I.R.S. Employer Identification No.) 265 EXCHANGE DRIVE ...
AptarGroup(ATR) - 2025 Q1 - Earnings Call Transcript
2025-05-02 14:02
AptarGroup (ATR) Q1 2025 Earnings Call May 02, 2025 09:00 AM ET Company Participants Mary Skafidas - Senior VP of IR & Corporate CommunicationsStephan Tanda - President, CEO & Executive DirectorVanessa Kanu - Executive VP & CFOGeorge Staphos - Managing Director Conference Call Participants Ghansham Panjabi - Senior Research AnalystMatthew Roberts - Equity Research AnalystDaniel Rizzo - AnalystMatt Larew - Research Analyst - HealthcareGabe Hajde - Analyst Operator Ladies and gentlemen, thank you for standing ...
AptarGroup(ATR) - 2025 Q1 - Earnings Call Transcript
2025-05-02 14:02
AptarGroup (ATR) Q1 2025 Earnings Call May 02, 2025 09:00 AM ET Company Participants Mary Skafidas - Senior VP of IR & Corporate CommunicationsStephan Tanda - President, CEO & Executive DirectorVanessa Kanu - Executive VP & CFOGeorge Staphos - Managing Director Conference Call Participants Ghansham Panjabi - Senior Research AnalystMatthew Roberts - Equity Research AnalystDaniel Rizzo - AnalystMatt Larew - Research Analyst - HealthcareGabe Hajde - Analyst Operator Ladies and gentlemen, thank you for standing ...
AptarGroup(ATR) - 2025 Q1 - Earnings Call Transcript
2025-05-02 13:00
Financial Data and Key Metrics Changes - The company reported adjusted earnings per share of $1.2, with a neutralized increase of approximately 5% over the prior year period when accounting for currency effects and tax [4][15] - Reported sales decreased by 3%, with core sales remaining flat compared to the prior year period [14] - Adjusted EBITDA increased by 3% to $183 million, with adjusted diluted earnings per share at $1.2 compared to $1.22 in the prior year [14][15] Business Line Data and Key Metrics Changes - Pharma segment's core sales increased by 3%, with prescription core sales up 10% driven by strong demand for emergency medicines and therapeutics [16] - Consumer Healthcare core sales decreased by 10% due to softer demand for nasal decongestants and cough medicines [16] - Injectables core sales decreased by 8% due to tough comparisons from the prior year, while Active Materials Science solutions saw an 11% increase in core sales [16][18] - Beauty segment's core sales decreased by 3%, with prestige fragrance and facial skincare sales down 11% [19] - Closures segment's core sales decreased by 2%, with product sales growth offset by lower tooling sales [20] Market Data and Key Metrics Changes - The U.S. market showed signs of inventory normalization, while other regions have not yet experienced similar trends [6][37] - The company noted strong demand for GLP-1 and biologics in the injectables market, indicating robust order books [7][36] Company Strategy and Development Direction - The company is focused on long-term growth driven by macro trends such as healthcare decentralization and the growth of generic medicines [6][7] - The company is ramping up share repurchases, having repurchased over $80 million worth of shares in the first quarter [13] - The company emphasizes sustainability as a competitive advantage, having received multiple awards for its efforts [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in growth prospects despite current economic uncertainties, highlighting resilience in essential product markets [28][30] - The company anticipates a strong second quarter with positive contributions from all segments, particularly in Pharma and Beauty [30][31] - Management acknowledged the evolving tariff situation but expects limited net effects on operations [25][82] Other Important Information - The effective tax rate for the first quarter was 25.8%, reflecting a temporary surtax enacted in France [15] - Free cash flow for the quarter was $26 million, with a strong balance sheet showing a cash balance of $126 million [23][24] Q&A Session Summary Question: Insights on order patterns and inventory levels - Management noted a reacceleration in orders across various segments, with U.S. inventories normalizing but not yet seen in other regions [35][37] Question: Impact of GLP-1s on injectables - Strong demand for GLP-1s is noted, with the company ramping up capabilities to meet this demand [36] Question: Tax rate guidance for the second half of the year - The expected effective tax rate for the second half is projected to be in the range of 22% to 24% [43] Question: Inventory status in cold and cough products - Management indicated that the U.S. has seen some inventory normalization, while other regions have not yet experienced this [48][49] Question: Outlook for tooling activity - Management expressed optimism about tooling activity, indicating it is on the rise as customers seek to differentiate their products [105]
AptarGroup (ATR) Q1 Earnings Top Estimates
ZACKS· 2025-05-01 23:25
AptarGroup (ATR) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.45%. A quarter ago, it was expected that this maker of consumer-product dispensing systems would post earnings of $1.26 per share when it actually produced earnings of $1.52, delivering a surprise of 20.63%.Over the la ...